U.S. treatment guidelines: new version, October 2005.
For those beginning antiretrovirals, the guidelines now say that the combination of an NNRTI + didanosine plus tenofovir should not be used, due to virologic failure and development of resistance. And the guidelines do not recommend ritonavir-boosted tipranavir in treatment-naive patients, due to the lack of clinical-trial data.
For experienced patients, "This section has been updated to redefine the goal of antiretroviral therapy in the management of treatment-experienced patients with virologic failure and to review the role of more potent ritonavir-boosted protease inhibitors such as tipranavir with or without enfuvirtide in these patients."
Much of the guidelines material is presented in a series of tables. The second page, titled "What's New in the Document," also notes the tables that have been changed.
This and other U.S. government guidelines are available at http://www.aidsinfo.nih.gov/guidelines/
|Printer friendly Cite/link Email Feedback|
|Publication:||AIDS Treatment News|
|Date:||Sep 30, 2005|
|Previous Article:||Major U.S. treatment-access problems likely: inadequate political response.|
|Next Article:||New California law: insurers cannot deny organ transplants solely because of HIV.|